Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Amicus Therapeutics, Inc. (FOLD) since 2007 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Amicus Therapeutics, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1178879.
Total stock buying since 2007: $164,927,777.
Total stock sales since 2007: $289,464,081.
Total stock option exercises since 2007: $43,076,426.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 400 | $4,000 | 400 | $3,611 |
| 2024 | 0 | $0 | 399,658 | $5,124,634 | 182,067 | $1,360,541 |
| 2023 | 0 | $0 | 813,767 | $10,307,679 | 457,240 | $2,081,221 |
| 2022 | 0 | $0 | 424,370 | $4,449,738 | 116,155 | $466,726 |
| 2021 | 45,105 | $451,689 | 557,791 | $7,173,882 | 411,757 | $2,127,182 |
| 2020 | 11,000 | $175,512 | 1,681,390 | $24,511,559 | 1,284,060 | $8,873,723 |
| 2019 | 4,945 | $49,796 | 572,269 | $6,783,107 | 547,724 | $2,955,368 |
| 2018 | 1,235,827 | $15,744,014 | 301,765 | $4,590,161 | 201,765 | $1,644,814 |
| 2017 | 1,501,395 | $18,395,032 | 971,072 | $12,606,562 | 913,823 | $11,449,856 |
| 2016 | 592,950 | $3,020,945 | 1,260,420 | $8,649,277 | 156,358 | $50,864 |
| 2015 | 810,000 | $5,440,410 | 1,080,786 | $13,931,432 | 1,273,641 | $11,766,749 |
| 2014 | 6,467,084 | $30,224,665 | 11,682,909 | $62,446,695 | 16,491 | $10,521 |
| 2013 | 1,525,000 | $3,085,000 | 0 | $0 | 0 | $0 |
| 2012 | 9,361,554 | $55,128,673 | 0 | $0 | 49,931 | $31,955 |
| 2011 | 30,000 | $162,800 | 2,250 | $16,875 | 2,250 | $1,435 |
| 2010 | 11,898 | $43,903 | 0 | $0 | 0 | $0 |
| 2009 | 20,000 | $82,600 | 71,908 | $765,927 | 5,924 | $8,466 |
| 2008 | 1,834,162 | $27,685,294 | 677,689 | $127,429,143 | 153,582 | $191,652 |
| 2007 | 461,042 | $5,237,444 | 44,894 | $673,410 | 81,102 | $51,742 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-01-02 | Andrews Kurt J. (SVP, Human Resources) | Sale | 10,000 | 14.72 | 147,190 |
| 2018-01-02 | Andrews Kurt J. (SVP, Human Resources) | Option Ex | 10,000 | 14.72 | 147,190 |
| 2018-01-02 | Barth Jay (Chief Medical Officer) | Sale | 5,000 | 14.71 | 73,560 |
| 2018-01-02 | Barth Jay (Chief Medical Officer) | Option Ex | 5,000 | 14.71 | 73,560 |
| 2018-01-02 | Baird William D Iii (Chief Financial Officer) | Sale | 10,000 | 14.72 | 147,180 |
| 2018-01-02 | Baird William D Iii (Chief Financial Officer) | Option Ex | 10,000 | 14.72 | 147,180 |
| 2018-01-02 | Quimi Daphne (SVP, Finance) | Sale | 8,000 | 14.71 | 117,720 |
| 2018-01-02 | Quimi Daphne (SVP, Finance) | Option Ex | 8,000 | 14.71 | 117,720 |
| 2018-01-02 | Raab Michael (Director) | Sale | 9,366 | 15.00 | 140,490 |
| 2018-01-02 | Raab Michael (Director) | Option Ex | 9,366 | 15.00 | 140,490 |
| 2018-01-02 | Hayden Donald J Jr (Director) | Sale | 20,000 | 15.00 | 300,000 |
| 2018-01-02 | Hayden Donald J Jr (Director) | Option Ex | 20,000 | 15.00 | 300,000 |
| 2017-12-29 | Crowley John F (Chairman & CEO) | Sale | 5,920 | 14.75 | 87,320 |
| 2017-12-29 | Crowley John F (Chairman & CEO) | Option Ex | 5,920 | 14.75 | 87,320 |
| 2017-12-28 | Crowley John F (Chairman & CEO) | Sale | 13,050 | 14.75 | 192,500 |
| 2017-12-28 | Crowley John F (Chairman & CEO) | Option Ex | 13,050 | 14.75 | 192,500 |
| 2017-12-21 | Crowley John F (Chairman & CEO) | Sale | 506 | 13.51 | 6,835 |
| 2017-12-21 | Crowley John F (Chairman & CEO) | Option Ex | 506 | 13.51 | 6,835 |
| 2017-12-20 | Crowley John F (Chairman & CEO) | Sale | 65,075 | 13.51 | 878,902 |
| 2017-12-20 | Crowley John F (Chairman & CEO) | Option Ex | 65,075 | 13.51 | 878,902 |
| 2017-12-11 | Crowley John F (Chairman & CEO) | Sale | 12,206 | 13.52 | 164,976 |
| 2017-12-11 | Crowley John F (Chairman & CEO) | Option Ex | 12,206 | 13.52 | 164,976 |
| 2017-12-04 | Crowley John F (Chairman & CEO) | Sale | 47,213 | 13.61 | 642,757 |
| 2017-12-04 | Crowley John F (Chairman & CEO) | Option Ex | 47,213 | 13.61 | 642,757 |
| 2017-12-01 | Barth Jay (Chief Medical Officer) | Sale | 5,000 | 13.59 | 67,935 |
| 2017-12-01 | Barth Jay (Chief Medical Officer) | Option Ex | 5,000 | 13.59 | 67,935 |
| 2017-10-18 | Crowley John F (Chairman & CEO) | Sale | 19,013 | 14.76 | 280,536 |
| 2017-10-18 | Crowley John F (Chairman & CEO) | Option Ex | 19,013 | 14.76 | 280,536 |
| 2017-10-17 | Crowley John F (Chairman & CEO) | Sale | 52,722 | 14.75 | 777,649 |
| 2017-10-17 | Crowley John F (Chairman & CEO) | Option Ex | 52,722 | 14.75 | 777,649 |
| 2017-10-16 | Crowley John F (Chairman & CEO) | Sale | 47,135 | 14.75 | 695,241 |
| 2017-10-16 | Crowley John F (Chairman & CEO) | Option Ex | 47,135 | 14.75 | 695,241 |
| 2017-10-13 | Crowley John F (Chairman & CEO) | Sale | 22,160 | 14.75 | 326,860 |
| 2017-10-13 | Crowley John F (Chairman & CEO) | Option Ex | 22,160 | 14.75 | 326,860 |
| 2017-10-12 | Barth Jay (Chief Medical Officer) | Sale | 5,000 | 14.25 | 71,270 |
| 2017-10-12 | Barth Jay (Chief Medical Officer) | Option Ex | 5,000 | 14.25 | 71,270 |
| 2017-10-12 | Do Hung (Chief Science Officer) | Sale | 50,194 | 14.25 | 715,364 |
| 2017-10-12 | Do Hung (Chief Science Officer) | Option Ex | 50,194 | 14.25 | 715,364 |
| 2017-10-12 | Baird William D Iii (Chief Financial Officer) | Sale | 40,000 | 14.25 | 570,120 |
| 2017-10-12 | Baird William D Iii (Chief Financial Officer) | Option Ex | 40,000 | 14.25 | 570,120 |
| 2017-10-12 | Quimi Daphne (SVP, Finance) | Sale | 7,000 | 14.25 | 99,743 |
| 2017-10-12 | Quimi Daphne (SVP, Finance) | Option Ex | 7,000 | 14.25 | 99,743 |
| 2017-10-12 | Crowley John F (Chairman & CEO) | Sale | 380,000 | 14.25 | 5,415,000 |
| 2017-10-12 | Crowley John F (Chairman & CEO) | Option Ex | 380,000 | 14.25 | 5,415,000 |
| 2017-10-12 | Raab Michael (Director) | Sale | 10,000 | 14.25 | 142,530 |
| 2017-10-12 | Raab Michael (Director) | Option Ex | 10,000 | 14.25 | 142,530 |
| 2017-09-26 | Crowley John F (Chairman & CEO) | Buy | 1,395 | 14.36 | 20,032 |
| 2017-07-13 | Edelman Joseph (10% Owner) | Buy | 1,500,000 | 12.25 | 18,375,000 |
| 2017-06-19 | Barth Jay (Chief Medical Officer) | Sale | 30,000 | 10.00 | 300,000 |
| 2017-06-19 | Barth Jay (Chief Medical Officer) | Option Ex | 30,000 | 10.00 | 300,000 |
| 2017-06-15 | Barth Jay (Chief Medical Officer) | Option Ex | 1,629 | 8.79 | 14,318 |
| 2017-05-19 | Do Hung (Chief Science Officer) | Sale | 29,914 | 8.00 | 239,312 |
| 2017-05-15 | Do Hung (Chief Science Officer) | Sale | 29,914 | 8.00 | 239,312 |
| 2017-03-02 | Campbell Bradley L (Chief Operating Officer) | Sale | 49,050 | 8.00 | 392,400 |
| 2017-02-07 | Do Hung (Chief Science Officer) | Sale | 25,000 | 6.00 | 150,000 |
| 2017-01-13 | Do Hung (Chief Science Officer) | Sale | 25,000 | 6.00 | 150,000 |
| 2017-01-03 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 100,000 | .00 | 0 |
| 2016-12-30 | Perceptive Life Sciences Master Fund Ltd | Buy | 94,750 | 4.96 | 470,054 |
| 2016-12-29 | Perceptive Life Sciences Master Fund Ltd | Buy | 94,750 | 4.85 | 459,916 |
| 2016-12-28 | Perceptive Life Sciences Master Fund Ltd | Buy | 47,375 | 4.91 | 232,706 |
| 2016-12-23 | Perceptive Life Sciences Master Fund Ltd | Buy | 85,275 | 4.82 | 411,025 |
| 2016-12-22 | Perceptive Life Sciences Master Fund Ltd | Buy | 189,500 | 4.51 | 854,834 |
| 2016-11-09 | Quimi Daphne (SVP, Finance) | Sale | 8,546 | 8.00 | 68,368 |
| 2016-11-09 | Quimi Daphne (SVP, Finance) | Option Ex | 2,858 | 8.00 | 22,864 |
| 2016-11-01 | Do Hung (Chief Science Officer) | Sale | 25,000 | 7.00 | 175,000 |
| 2016-10-03 | Do Hung (Chief Science Officer) | Sale | 25,000 | 7.25 | 181,250 |
| 2016-09-20 | Baird William D Iii (Chief Financial Officer) | Sale | 20,500 | 8.00 | 164,041 |
| 2016-09-20 | Baird William D Iii (Chief Financial Officer) | Option Ex | 3,500 | 8.00 | 28,000 |
| 2016-09-06 | Do Hung (Chief Science Officer) | Sale | 25,000 | 7.00 | 175,000 |
| 2016-08-25 | Perceptive Life Sciences Master Fund Ltd | Sale | 1,100,000 | 6.81 | 7,491,000 |
| 2016-08-04 | Barth Jay (Chief Medical Officer) | Sale | 10,458 | 7.00 | 73,206 |
| 2016-08-04 | Do Hung (Chief Science Officer) | Sale | 25,000 | 7.00 | 175,000 |
| 2016-07-27 | Barth Jay (Chief Medical Officer) | Sale | 20,916 | 7.00 | 146,412 |
| 2016-06-03 | Green Jeremy | Buy | 66,300 | 7.20 | 477,360 |
| 2016-06-02 | Rosenberg Ellen (General Counsel & Corp. Secy) | Buy | 15,000 | 7.67 | 115,050 |
| 2016-01-04 | Baird William D Iii (Chief Financial Officer) | Option Ex | 50,000 | .00 | 0 |
| 2016-01-04 | Quimi Daphne (Vice President Finance) | Option Ex | 25,000 | .00 | 0 |
| 2016-01-04 | Peist Kenneth (VP, Legal & IP) | Option Ex | 25,000 | .00 | 0 |
| 2016-01-04 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 50,000 | .00 | 0 |
| 2015-12-03 | Barth Jay (Chief Medical Officer) | Option Ex | 25,000 | .00 | 0 |
| 2015-11-10 | Mcglynn Margaret G (Director) | Buy | 10,000 | 10.27 | 102,660 |
| 2015-10-07 | Crowley John F (Chairman & CEO) | Option Ex | 13,193 | 6.45 | 85,094 |
| 2015-10-07 | Perceptive Life Sciences Master Fund Ltd | Buy | 50,000 | 6.27 | 313,500 |
| 2015-10-06 | Perceptive Life Sciences Master Fund Ltd | Buy | 250,000 | 6.49 | 1,621,750 |
| 2015-10-05 | Perceptive Life Sciences Master Fund Ltd | Buy | 500,000 | 6.80 | 3,402,500 |
| 2015-10-01 | Quimi Daphne (Vice President Finance) | Sale | 11,250 | 13.13 | 147,757 |
| 2015-10-01 | Quimi Daphne (Vice President Finance) | Option Ex | 11,250 | 13.13 | 147,757 |
| 2015-10-01 | Peist Kenneth (VP, Legal & IP) | Sale | 10,000 | 13.14 | 131,360 |
| 2015-10-01 | Peist Kenneth (VP, Legal & IP) | Option Ex | 10,000 | 13.14 | 131,360 |
| 2015-09-21 | Baird William D Iii (Chief Financial Officer) | Sale | 15,236 | 16.78 | 255,629 |
| 2015-09-21 | Baird William D Iii (Chief Financial Officer) | Option Ex | 15,236 | 16.78 | 255,629 |
| 2015-09-21 | Campbell Bradley L (Chief Operating Officer) | Sale | 13,001 | 16.78 | 218,208 |
| 2015-09-21 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 13,001 | 16.78 | 218,208 |
| 2015-09-15 | Do Hung (Chief Science Officer) | Sale | 25,000 | 17.75 | 443,675 |
| 2015-09-14 | Quimi Daphne (Vice President Finance) | Sale | 2,500 | 18.08 | 45,199 |
| 2015-07-16 | Crowley John F (Chairman & CEO) | Sale | 16,025 | 16.00 | 256,400 |
| 2015-07-16 | Crowley John F (Chairman & CEO) | Option Ex | 16,025 | 16.00 | 256,400 |
| 2015-07-14 | Crowley John F (Chairman & CEO) | Sale | 142,250 | 15.03 | 2,137,733 |
| 2015-07-14 | Crowley John F (Chairman & CEO) | Option Ex | 142,250 | 15.03 | 2,137,733 |
| 2015-07-13 | Valenzano Ken (SVP, Pharmacology & Biology) | Sale | 15,000 | 15.00 | 225,000 |
| 2015-07-13 | Valenzano Ken (SVP, Pharmacology & Biology) | Option Ex | 15,000 | 15.00 | 225,000 |
| 2015-07-13 | Crowley John F (Chairman & CEO) | Sale | 7,750 | 15.01 | 116,312 |
| 2015-07-13 | Crowley John F (Chairman & CEO) | Option Ex | 7,750 | 15.01 | 116,312 |
| 2015-07-13 | Sblendorio Glenn (Director) | Sale | 10,000 | 15.00 | 150,000 |
| 2015-07-13 | Sblendorio Glenn (Director) | Option Ex | 10,000 | 15.00 | 150,000 |
| 2015-07-08 | Doshi Dipal (SVP Strategy & Bus Dev) | Sale | 6,250 | 13.87 | 86,687 |
| 2015-07-07 | Doshi Dipal (SVP Strategy & Bus Dev) | Option Ex | 12,500 | .00 | 0 |
| 2015-07-01 | Gershkowitz Jayne (SVP, Chief Patient Advocate) | Sale | 10,649 | 13.97 | 148,819 |
| 2015-07-01 | Gershkowitz Jayne (SVP, Chief Patient Advocate) | Option Ex | 10,649 | 13.97 | 148,819 |
| 2015-07-01 | Quimi Daphne (Vice President Finance) | Sale | 2,600 | 13.98 | 36,350 |
| 2015-07-01 | Quimi Daphne (Vice President Finance) | Option Ex | 2,600 | 13.98 | 36,350 |
| 2015-07-01 | Peist Kenneth (VP, Legal & IP) | Sale | 10,000 | 13.98 | 139,770 |
| 2015-07-01 | Peist Kenneth (VP, Legal & IP) | Option Ex | 10,000 | 13.98 | 139,770 |
| 2015-06-23 | Hayden Donald J Jr (Director) | Sale | 55,000 | 14.01 | 770,385 |
| 2015-06-23 | Hayden Donald J Jr (Director) | Option Ex | 55,000 | 14.01 | 770,385 |
| 2015-06-22 | Castelli Jeff (SVP, Program Management) | Sale | 18,981 | 13.94 | 264,633 |
| 2015-06-22 | Castelli Jeff (SVP, Program Management) | Option Ex | 18,981 | 13.94 | 264,633 |
| 2015-06-22 | Valenzano Ken (SVP, Pharmacology & Biology) | Sale | 20,500 | 13.85 | 284,007 |
| 2015-06-22 | Valenzano Ken (SVP, Pharmacology & Biology) | Option Ex | 20,500 | 13.85 | 284,007 |
| 2015-06-19 | Baird William D Iii (Chief Financial Officer) | Sale | 15,235 | 13.26 | 202,061 |
| 2015-06-19 | Baird William D Iii (Chief Financial Officer) | Option Ex | 15,235 | 13.26 | 202,061 |
| 2015-06-19 | Dilone Enrique (SVP, Technical Operations) | Sale | 14,045 | 13.26 | 186,278 |
| 2015-06-19 | Dilone Enrique (SVP, Technical Operations) | Option Ex | 14,045 | 13.26 | 186,278 |
| 2015-06-19 | Campbell Bradley L (Chief Operating Officer) | Sale | 13,000 | 13.26 | 172,419 |
| 2015-06-19 | Campbell Bradley L (Chief Operating Officer) | Option Ex | 13,000 | 13.26 | 172,419 |
| 2015-06-15 | Yu Julie (VP Clinical Ops & Data Mgmt) | Sale | 8,195 | 14.17 | 116,123 |
| 2015-06-15 | Castelli Jeff (SVP, Program Management) | Sale | 7,377 | 14.17 | 104,532 |
| 2015-06-08 | Castelli Jeff (SVP, Program Management) | Sale | 17,312 | 12.87 | 222,805 |
| 2015-06-08 | Castelli Jeff (SVP, Program Management) | Option Ex | 17,312 | 12.87 | 222,805 |
| 2015-06-08 | Crowley John F (Chairman & CEO) | Sale | 55,000 | 13.01 | 715,550 |
| 2015-06-08 | Crowley John F (Chairman & CEO) | Option Ex | 55,000 | 13.01 | 715,550 |
| 2015-05-11 | Yu Julie (VP Clinical Ops & Data Mgmt) | Sale | 7,500 | 10.85 | 81,337 |
| 2015-05-11 | Castelli Jeff (SVP, Program Management) | Sale | 10,000 | 10.84 | 108,370 |
| 2015-05-11 | Gershkowitz Jayne (SVP, Chief Patient Advocate) | Sale | 10,000 | 10.84 | 108,390 |
| 2015-05-11 | Baird William D Iii (Chief Financial Officer) | Sale | 24,800 | 10.84 | 268,807 |
| 2015-05-11 | Quimi Daphne (VP Finance and Controller) | Sale | 7,500 | 10.84 | 81,307 |
| 2015-05-11 | Dilone Enrique (SVP, Technical Operations) | Sale | 10,000 | 10.85 | 108,450 |
| 2015-05-11 | Peist Kenneth (VP, Legal & IP) | Sale | 12,500 | 10.84 | 135,487 |
| 2015-05-11 | Valenzano Ken (SVP, Pharmacology & Biology) | Sale | 13,000 | 10.85 | 140,998 |
| 2015-05-11 | Kirk John (VP, Regulatory Affairs) | Sale | 10,000 | 10.84 | 108,360 |
| 2015-05-11 | Campbell Bradley L (Chief Operating Officer) | Sale | 24,800 | 10.84 | 268,807 |
| 2015-05-08 | Barth Jay (Chief Medical Officer) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Yu Julie (VP Clinical Ops & Data Mgmt) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Castelli Jeff (SVP, Program Management) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Gershkowitz Jayne (SVP, Chief Patient Advocate) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Baird William D Iii (Chief Financial Officer) | Option Ex | 50,000 | .00 | 0 |
| 2015-05-08 | Quimi Daphne (VP Finance and Controller) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Dilone Enrique (SVP, Technical Operations) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Peist Kenneth (VP, Legal & IP) | Option Ex | 25,000 | .00 | 0 |
| 2015-05-08 | Valenzano Ken (SVP, Pharmacology & Biology) | Option Ex | 25,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of FOLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Amicus Therapeutics, Inc. (symbol FOLD, CIK number 1178879) see the Securities and Exchange Commission (SEC) website.